Functionally Validated Structural Endpoints for Early AMD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

556 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-07

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD). This research plan is designed to elucidate the structural (anatomical) basis of this visual deficit using cellular- and subcellular level imaging of the retina and its supporting tissues in living people. An accurate map and timeline of structure-function relationships in persons tested for night vision will result in functionally validated structural endpoints for early AMD trials, as well as define major biologic effects for development into future treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator

NCT03166202

Age-related Macular Degeneration

COMPLETED

Dark Adaptation in Participants With Age-Related Macular Degeneration

NCT03225131

Age-Related Macular Degeneration

ACTIVE_NOT_RECRUITING

Rod and Cone Mediated Function in Retinal Disease

NCT02617966

Retinal Degeneration Retinitis Pigmentosa Stargardt's Disease

RECRUITING

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

NCT03478865

AMD

COMPLETED EARLY_PHASE1

Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation

NCT03478878

Reticular Pseudodrusen (RPD) Age-Related Macular Degeneration

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Alabama Study on Early Age-Related Macular Degeneration 2 (ALSTAR2) is a prospective cohort study with baseline measurements that are repeated at follow-up 3 years later. The baseline and 3 year follow-up visits will each consist of 2 visits for a total of 4 visits.

Study assessments are listed below. All are collected at two visits at both baseline and follow-up for 4 visits total (blood collection for DNA analysis at baseline only). For some functional tests (photopic and mesonic acuity, photopic and mesonic contrast sensitivity), each eye will be tested separately. For other functional tests (dark-adapted two-color perimetry, light-adapted cone-mediate perimetry, rod-mediated dark adaptation), only one eye will be tested, which will be designated by the study eye. Tropicamide 1% and phenylephrine hydrochloride 2.5% are used to dilate pupils (diameter of ≥ 6 mm) as needed for specific parts of the protocol. After completing the baseline visits, participants will receive an annual phone call from the study coordinator so that contact information can be updated. Participants will receive an annual newsletter containing study related information (this will be submitted to the IRB for approval).

Study Assessments:

1. Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light.
2. Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors.
3. Photopic and mesopic acuity in central vision, as measured by letter charts..
4. Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts..
5. Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative), OCT-angiography (OCT-A).
6. Blood draw for the analysis of C-reactive protein, high-density lipoprotein, carotenoid level, DNA extraction, and examination of the presence of genetic risk associated with age-related macular degeneration (AMD).
7. Questionnaires: Demographics, medical co-morbidities, cognitive status screen, medication use, alcohol use, smoking, self-reported visual difficulty in the visual activities of daily living

The Young normal group will only complete:

1. Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light.
2. Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors.
3. . Photopic and mesopic acuity in central vision, as measured by letter charts..
4. Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts..
5. Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative),OCT-angiography (OCT-A).d and quantitative), OCT-angiography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-related Macular Degeneration Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Macular Health

\>=60 years old with no macular disease

Normal Macular Health

Intervention Type OTHER

This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Early Macular Degeneration

\>=60 years old with early age-related macular degeneration

Early Macular Degeneration

Intervention Type OTHER

This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Young Normals

20-30 years old with normal macular health

Young Normals

Intervention Type OTHER

This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal Macular Health

This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Intervention Type OTHER

Early Macular Degeneration

This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Intervention Type OTHER

Young Normals

This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For those in Normal Macular Health or Early AMD: aged ≥ 60 years; either have normal macular health in both eyes at baseline or have early AMD in one eye For Young Normals: aged 20-30 years old; normal macular health in both eyes.

Exclusion Criteria

Exclusion for those in normal macular health are:

* ANY EYE CONDITION OR DISEASE IN EITHER EITHER (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING:
* diabetic retinopathy
* glaucoma
* ocular hypertension
* history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations)
* optic neuritis
* corneal disease
* previous ocular trauma or surgery
* REFRACTIVE ERROR \>- 6 DIOPTERS
* NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING:
* multiple sclerosis
* Parkinson disease
* stroke
* Alzheimer disease
* seizure disorders
* brain tumor
* traumatic brain injury
* PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY:
* to follow simple directions
* answer questions about health and functioning
* or to provide informed consent
* DIABETES
* ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRALITY OR IS BELIEVED TO BE TERMINAL.

These are identical to those described above, except that it is acceptable for participants to have early AMD (AREDS 2-4) in one eye and be AREDS grade 1 or any stage of AMD in the fellow eye.

Exclusion for Young Normals:

* ANY EYE CONDITION OR DISEASE IN EITHER EYE (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING:
* diabetic retinopathy
* glaucoma
* ocular hypertension
* history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations)
* optic neuritis, corneal disease
* previous ocular trauma or surgery
* RERACTIVE ERROR \>=6 DIOPTORS
* NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING:
* multiple sclerosis
* Parkinson disease
* stroke
* Alzheimer disease
* seizure disorders
* brain tumor
* traumatic brain injury
* PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY TO:
* follow simple directions
* answer questions about health and functioning
* or to provide informed consent
* DIABETES
* ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRAILTY OR IS BELIEVED TO BE TERMINAL.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes